Ubs Group Ag Stoke Therapeutics, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 352,715 shares of STOK stock, worth $7.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

352,715

Previous 171,831 105.27%

Holding current value

$7.76 Million

Previous $1.14 Million 250.53%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$5.9 - $11.84 $1.07 Million - $2.14 Million	180,884 Added 105.27%	352,715 $4 Million
Q1 2025 May 13, 2025	SELL	$6.65 - $12.74 $39,986 - $76,605	-6,013 Reduced 3.38%	171,831 $1.14 Million
Q4 2024 Feb 14, 2025	BUY	$10.8 - $13.92 $1.07 Million - $1.39 Million	99,532 Added 127.1%	177,844 $1.96 Million
Q3 2024 Nov 14, 2024	SELL	$12.24 - $15.92 $488,890 - $635,876	-39,942 Reduced 33.78%	78,312 $962,000
Q2 2024 Aug 13, 2024	BUY	$11.03 - $17.52 $869,594 - $1.38 Million	78,839 Added 200.02%	118,254 $1.6 Million
Q1 2024 May 13, 2024	BUY	$4.12 - $14.17 $39,725 - $136,627	9,642 Added 32.39%	39,415 $532,000
Q4 2023 Feb 09, 2024	BUY	$3.37 - $5.4 $32,008 - $51,289	9,498 Added 46.85%	29,773 $156,000
Q3 2023 Nov 09, 2023	SELL	$3.78 - $11.99 $10,606 - $33,643	-2,806 Reduced 12.16%	20,275 $79,000
Q2 2023 Aug 11, 2023	BUY	$7.93 - $13.82 $71,401 - $124,435	9,004 Added 63.96%	23,081 $245,000
Q1 2023 May 12, 2023	SELL	$7.65 - $10.38 $5,056 - $6,861	-661 Reduced 4.49%	14,077 $117,000
Q4 2022 Feb 08, 2023	BUY	$7.07 - $15.69 $78,095 - $173,311	11,046 Added 299.19%	14,738 $136,000
Q3 2022 Nov 10, 2022	BUY	$12.56 - $22.53 $46,371 - $83,180	3,692 New	3,692 $47,000
Q2 2022 Aug 10, 2022	SELL	$10.36 - $23.93 $538,108 - $1.24 Million	-51,941 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$17.19 - $26.1 $148,934 - $226,130	8,664 Added 20.02%	51,941 $1.09 Million
Q4 2021 Feb 14, 2022	BUY	$18.11 - $30.72 $189,503 - $321,454	10,464 Added 31.89%	43,277 $1.04 Million
Q3 2021 Nov 15, 2021	BUY	$23.65 - $34.44 $675,704 - $983,985	28,571 Added 673.53%	32,813 $835,000
Q2 2021 Aug 13, 2021	SELL	$30.53 - $41.09 $338,058 - $454,989	-11,073 Reduced 72.3%	4,242 $143,000
Q1 2021 May 12, 2021	BUY	$36.08 - $69.81 $552,565 - $1.07 Million	15,315 New	15,315 $595,000
Q2 2020 Jul 31, 2020	SELL	$20.26 - $29.73 $88,738 - $130,217	-4,380 Closed	0 $0
Q1 2020 May 01, 2020	SELL	$16.8 - $34.15 $80,119 - $162,861	-4,769 Reduced 52.13%	4,380 $100,000
Q4 2019 Feb 14, 2020	BUY	$20.01 - $30.79 $61,530 - $94,679	3,075 Added 50.63%	9,149 $259,000
Q3 2019 Nov 14, 2019	BUY	$20.53 - $37.72 $93,493 - $171,776	4,554 Added 299.61%	6,074 $131,000
Q2 2019 Aug 14, 2019	BUY	$25.53 - $29.17 $38,805 - $44,338	1,520 New	1,520 $44,000

Others Institutions Holding STOK

# of Institutions

139

Shares Held

57.6M

Call Options Held

2.7K

Put Options Held

57.4K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $867M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account